FutureMeds Warszawa Centrum

The trials here

What the 5 trials at this site are about, from their registry records.

Conditions

• Obesity2 trials
• Sjögren's disease2 trials
• Type 2 diabetes2 trials

Phase

• Phase 34 trials
• Phase 21 trial

Status

• Completed2 trials
• Recruiting2 trials
• Active, not recruiting1 trial

Lead sponsor

• Ascletis Pharma (China) Co. Ltd.2 trials
• Amgen1 trial
• Corxel Pharmaceuticals Inc.1 trial
• Horizon Therapeutics Ireland Designated Activity Company1 trial

Running trials

• Recruiting

  Efficacy and Safety of Once-Daily Oral ASC30 Compared with Placebo in Participants with Obesity or Overweight with Type 2 Diabetes Mellitus

  2026-526336-39-00· Phase 3· Ascletis Pharma (China) Co. Ltd.· Source

• Recruiting

  Efficacy and Safety of Once-Daily Oral ASC30 Compared with Placebo in Participants with Obesity or Overweight with Weight-Related Comorbidities

  2026-526172-23-00· Phase 3· Ascletis Pharma (China) Co. Ltd.· Source

• Active, not recruiting

  A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Finding Study of CX11 Tablets in Patients with Type 2 Diabetes Mellitus

  2025-524514-28-00· Phase 2· Corxel Pharmaceuticals Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Obesity2 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Completed

  A study to find how well Dazodalibep works and how safe it is in participants with Sjögren’s Syndrome

  2023-503923-24-00· Phase 3· Horizon Therapeutics Ireland Designated Activity Company· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity

  NCT06104124· Phase 3· Amgen· Source